SAB Biotherapeutics (SABS) Shares Outstanding (2020 - 2026)

SAB Biotherapeutics has reported Shares Outstanding for 7 years, with the latest figure at $75.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 711.0% year-over-year to $75.8 million; the trailing twelve-month figure through Mar 2026 stood at $75.8 million (up 711.0% YoY), and the FY2025 full-year result was $47.7 million, up 113335.74% from the prior year.
• Shares Outstanding for Q1 2026 stood at $75.8 million, up from $47.7 million in the prior quarter.
• The five-year high for Shares Outstanding was $75.7 million in Q1 2026, with the low at -$546658.0 in Q1 2022.
• Historically, Shares Outstanding has averaged $13.7 million across 5 years, with a median of $9.3 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding slumped 102.1% — and 2025, when it jumped 113335.74%.
• SAB Biotherapeutics' Shares Outstanding stood at $5.1 million in 2022, then jumped by 82.18% to $9.3 million in 2023, then slumped by 99.55% to $42019.0 in 2024, then jumped by 113335.74% to $47.7 million in 2025, then jumped by 59.03% to $75.8 million in 2026.
• The last three Shares Outstanding figures came in at $75.8 million (Q1 2026), $47.7 million (Q4 2025), and $638558.0 (Q3 2025), per Business Quant data.